With the aim of fulfilling its corporate philosophy of “help improve the quality of life of patients by serving as many people as possible to return smiles of happiness to their faces, through supplying superior pharmaceuticals,” the KAKEN Group provides drugs and information that contribute to the quality of life of patients from a distinctive viewpoint. We will continue striving to create value based on our unique strengths.
View Corporate Report 2025 – Value Creation Process
INPUT
Financial Capital
〜Sound financial position balanced with growth investments〜
• Operating cash flow •
¥29,780 million
• Equity ratio •
80.2%
Developing new drugs requires a long period of over ten years and substantial financial capital. To maintain our competitive advantage, it is crucial to sustain a sound financial position.
Manufacturing Capital
〜Operating base that
ensures stable supply〜
• Capital expenditures •
¥3,418 million
• Manufacturing base •
Shizuoka Factory
The Shizuoka Factory continuously invests in equipment to ensure a sustainable supply of pharmaceuticals and to enhance quality.
Human Capital
〜A team of professionals who help to achieve the “Three Joys”〜
• Number of employees (Kaken Pharmaceutical) •
1,103
• Average tenure (Kaken Pharmaceutical) •
Male 18.0 years Female 15.6 years
We are committed to fostering an environment where employees can find fulfillment in their work and building an organization where diverse talents collaborate as one team.
Intellectual Capital
〜The source of new treatment options for patients〜
• R&D investment •
¥18,725 million
• Number of projects in the development pipeline •
11
(As of June 2025)
Our company provides patients with new treatment options, primarily through dermatology and orthopedic products. In recent years, we have introduced development candidates for rare diseases, striving to eliminate drug lag and drug loss.
Social Capital
〜Building strong relationships with stakeholders〜
• Sales offices •
33
（As of April 2025）
• Number of countries/regions where efinaconazole has been launched •
6
Our company operates sales offices nationwide to promote the appropriate use of pharmaceuticals. Furthermore, as part of our global expansion, we are actively advancing the overseas launch of “Crenafin(INN:efinaconazole).”
Natural Capital
〜Eco-conscious business activities〜
• CO2 emissions •
20,136 t-CO2
• Water consumption •
3,044 thousand m3
Our company is committed to reducing environmental impact by striving to cut CO2 emissions and water usage, and we are advancing environmental management.
OUTPUT
Dermatology
Clenafin
Japan’s first topical treatment for onychomycosis
Fiblast
The world's first human bFGF (fibroblast growth factor) formulation
Ecclock
Japan's first NHI (National Health Insurance)-listed treatment for primary axillary hyperhidrosis
Orthopedics
Artz
The world’s first hyaluronic acid intra-articular injection
Hernicore
Japan’s first intradiscal enzyme injection therapy
Other Areas
Seprafilm
Our only medical device to reduce complications caused by post-surgical adhesions
Regroth
The world's first NHI-listed pharmaceutical for periodontal regenerative agent
: First in the world : First in Japan